Objective: To characterize pretreatment behavioral problems and differential effects of initial therapy in children with childhood absence epilepsy (CAE).
problems compared to patients taking ethosuximide (secondary outcome). [15] [16] [17] This report characterizes this trial's pretreatment behavior findings and subsequent differential medication behavioral effects (predefined tertiary outcome).
METHODS Primary research question. What are the differential behavioral effects of initial monotherapy medication in children with CAE?
Patient population. Details of the inclusion/exclusion criteria have been published previously. 16, 17 Briefly, children 2.5-13 years old with newly diagnosed CAE and EEG evidence of 2.7-3.5 Hz generalized spike-wave discharges, a normal background, and $1 burst lasting $3 seconds were enrolled. Children previously treated with antiepileptic drugs for .7 days or with a history of major psychiatric disease or autism were excluded. 16, 17 Study design. The study was a parallel, randomized, doubleblinded comparative effectiveness study (randomized controlled trial [RCT]), with partial crossover to open label (at treatment failure only) with subsequent long-term follow-up. [16] [17] [18] Participants had a pretreatment baseline visit including a detailed history and examination, a video EEG, age-specific battery of neuropsychological tests, 15 and parental questionnaires about behavior utilizing the Child Behavior Checklist (CBCL). 19, 20 Participants were randomized within age strata (younger or older than 6 years) equally to ethosuximide, lamotrigine, or valproic acid and continued receiving doubleblind study medication as long as they did not meet any treatment failure criteria. 16, 17 Measure of behavior. The CBCL, 19, 20 the primary measure of behavior, was administered at baseline, week [16] [17] [18] [19] [20] , and month 12 visits along with any discontinuation visit prior to month 12. The CBCL, an empirically based scale, is validated from age 1½ years through adulthood. For this study, the 1½-to 5-year-old and 6-to 18-year-old scales were used. All scales are normalized to a mean of 50 and SD of 10. Scores $70 are considered clinically significant. In the general pediatric population, approximately 2% of children are expected to have scores $70. 19, 20 The CBCL was centrally scored by one author (R.C.S.), who was blinded to study arm and treatment outcome.
Outcome measures. The primary behavior outcome was the CBCL total problems score. Four other CBCL scales were secondary behavior outcomes: internalizing problems, externalizing problems, syndrome scale for attention problems, and DSMoriented scale for attention-deficit/hyperactivity problems.
Cognitive data. The trial's cognitive testing methodology and results have been described previously. 15 The primary objective attention measure was the confidence index from the Conner Continuous Performance Test (CPT-II) and Kiddie CPT. The CPT confidence index value indicates the probability that the child has a clinically significant attention deficit. A confidence index $0.60 value indicates a $60% probability and is considered clinically significant. Commission and omission scores were also examined. 15, 21 Wisconsin Card Sorting Test perseverative response measured executive function. [15] [16] [17] Seizure freedom. Seizure freedom determination included both clinical and EEG assessments and has been described previously. 16, 17, 22 Participants were considered seizure-free if they were both clinically and electrographically seizure-free.
Statistical analysis. Baseline, week [16] [17] [18] [19] [20] , and month 12 CBCL outcome data were summarized as group means and percentage of individual scale scores $70. Week 16-20 CBCL scores included that visit's scores and scores from any earlier discontinuation visit after the week 4 visit. Similarly, month 12 CBCL scores included scores from earlier discontinuation visits after the week 16-20 visit. CPT confidence index values used a dichotomous grouping approach ($0.60 vs ,0.60).
Baseline demographics and EEG features 22 were compared using Fisher exact test, exact x 2 tests, t tests, or analysis of variance (ANOVA) as appropriate. Linear regression was used to determine whether clinical, demographic, EEG, and cognitive features, including CPT variables, were predictive of baseline CBCL outcome scores. CBCL scale scores at week 16-20 and month 12 were compared using exact x 2 test for percentages of scores $70 and ANOVA and analyses of covariance (ANCOVAs), correcting for baseline CBCL scores, for means, as prespecified in the protocol. Change scores were analyzed similarly. ANOVA/ANCOVA were also used to explore treatment by seizure freedom interaction in explaining CBCL outcomes. These analyses were post hoc and descriptive. All pairwise comparisons used a Bonferroni correction (p 5 0.017 for 3 pairwise comparisons between treatments).
Although the study's sample size of 446 was determined by the parent clinical trial, 16, 17 it was prespecified that a sample size of 112 patients per treatment group would be sufficient to detect a difference of 2 points on the overall CBCL total problems, attention problems, both syndrome and DSM, and externalizing and internalizing problems at the week 16-20 visit from the best treatment to the second and 3 points from the second to the worst with 80% power, while controlling for a 5 0.01 (5 outcome scales, Bonferroni correction).
All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) and StatXact version 8.0 (Cytel Inc., Cambridge, MA). A p value of ,0.05 was considered significant except as noted otherwise above.
Standard protocol approvals, registrations, and patient consents. All 32 site institutional review boards approved the study. Written parental informed consent and, when appropriate, child assent was obtained from all participants. The trial was conducted under a Food and Drug Administration-approved Investigational New Drug application and is listed at clinicaltrials.gov/ under NCT00088452.
RESULTS
Patient population. Baseline CBCL data were available from 382 (86%) of 446 RCT participants. The average age at study entry was 7.6 6 2.2 years, 57% were female, 75.4% were white, 17.3% were African American, and 23% were Hispanic. The cohort's baseline IQ was 95.15 6 15.5 (n 5 343, 95% CI 93.5-96.8). There were no significant differences in age, sex, ethnicity, treatment group assignment, or shortest seizure duration on baseline EEG between the 382 participants with baseline CBCL data and 64 participants without. A higher proportion of black participants did not have a baseline CBCL (31% vs 17.3%, p 5 0.012). There were no differences in baseline characteristics among the 3 treatment subgroups.
At week 16-20, completed CBCL data were available for 310 participants. At month 12, completed CBCL data were available for 168 participants (80% of 209 participants with freedom from failure at week 16-20 visit). There were no significant differences in age, sex, race, or ethnicity between the 310 participants with CBCL data at the week 16-20 visit and the 136 participants without, or between the 168 participants with CBCL data at the month 12 visit and the 278 participants without. There were substantially fewer participants initially assigned to lamotrigine still in the study at the month 12 visit, 17 so a higher percentage of lamotrigine participants did not have month 12 CBCL data compared to those in the other 2 treatment groups (figure 1).
Baseline CBCL scores. At baseline, 8% of participants had total problem scores $70 (95% CI 6%-11%), 5% had internalizing problems $70 (95% CI 3%-8%), 6% had externalizing problems $70 (95% CI 4%-9%), 15% had attention problems $70 (95% CI 12%-19%), and 7% had attentiondeficit/hyperactivity problems score $70 (95% CI 4.5%-10%). Attention problems also had the highest mean score (60.1 6 9.78) (table 1).
Parents were more likely to identify behavioral issues in children $6 years old (table 1) . Both mean total problems score and percentage of children with scores $70 were higher in the $6-year-old group compared to the younger group (53.9 6 10.7 vs 49.5 6 10.9, p 5 0.0010; 10% vs 1%, p 5 0.0032). Similarly, worse scores were noted for children $6 years for attention problems, internalizing, and externalizing scores (table 1) . There were no significant differences in baseline mean scores across the 3 treatment subgroups for the total problems score or the 4 subscales used (table 2) . However, more patients taking valproate had pretreatment total problems scores $70 (valproate 13%, ethosuximide 5%, lamotrigine 7%; p 5 0.034) and externalizing problems score $70 (valproate 10%, ethosuximide 3%, lamotrigine 4%; p 5 0.041) (table 2).
Factors associated with higher (worse) baseline total problems scores in a linear regression were age $6 years (p 5 0.0007), higher CPT confidence index (p 5 0.0001), higher CPT omission scores (p 5 0.0072), lower full-scale IQ (p , 0.0001), and lower verbal IQ (p 5 0.029). Each factor accounted for only 2%-6% of the variability in total problems score, and combined, for 10% variability. These factors along with higher perseverative response on Wisconsin Card Sorting Test scores were associated with worse externalizing problems and attention problems scores, accounting for 1%-10% of the variability individually, and 10%-20% combined. Factors associated with higher internalizing problems scores were age $6 years (p 5 0.0056), Hispanic ethnicity (p 5 0.018), shortest duration of seizure on EEG (p 5 0.044), higher CPT confidence index (p 5 0.016), and lower full-scale IQ (p 5 0.036), each accounting for 1%-2% of variability, and 5% when combined.
There was a correlation between baseline CPT confidence index scores and the CBCL attention score (p # 0.0001). A higher CPT confidence index . a Prespecified primary (total problems) and secondary study outcomes. b Ninety-five percent confidence interval for the overall total problems score was 6%-11%, internalizing problems score 3%-8%, externalizing problems score 4%-9%, attention problems score 12%-19%, and attention-deficit/hyperactivity problems score 4.5%-10%. Abbreviation: ANOVA 5 analysis of variance. All pairwise comparisons of differences both in mean scores and percentage scores were performed with a Bonferroni correction for 3 pairwise comparisons within each treatment (p 5 0.017 for significance), but not controlling for baseline. At the week 16-20 visit, the valproic acid group had worse total problems, externalizing problems, attention problems, and attention-deficit/hyperactivity problems mean scores compared to the ethosuximide group, with the 98.3% confidence interval not including 0. At the month 12 visit, the valproic acid group had worse attention problems mean scores compared to the ethosuximide group.
was associated with worse CBCL attention scores (figure e-1 at Neurology.org). When controlling for baseline scores, all pairwise differences remained significant. In addition, patients taking valproic acid had significantly worse total problems, internalizing problems, externalizing problems, and attention-deficit/hyperactivity problems mean scores compared to patients taking lamotrigine (table e-1).
At week 16-20, there were no differences in CBCL outcomes between those with freedom from failure (n 5 174) and those without (n 5 136) or those who attained seizure freedom (n 5 200) and those who did not (n 5 110).
At the week 16-20 visit, participants with baseline CPT confidence index $0.60 (n 5 96) had significantly worse total problems, externalizing problems, attention problems, attention-deficit/hyperactivity problems, aggressive behavior, and oppositional defiant behavioral scores than those with confidence index scores ,0.60 (n 5 184).
For the 278 participants who had a CBCL at baseline and at week 16-20, there was modest improvement (p , 0.001) between visits in total problems score and the 4 secondary behavioral outcomes (table 3) . Within these 278 participants, when correcting for baseline CBCL scores, participants achieving freedom from failure (n 5 153) had better total problems scores (48.1 6 11.97 vs 50.4 6 10.44, p 5 0.030), externalizing problems scores (47.9 6 11.30 vs 49.2 6 10.14, p 5 0.043), and attention problems scores (55.7 6 7.32 vs 57.7 6 9.08, p 5 0.032) compared to those experiencing treatment failure (n 5 125). Among these 278 participants, there were no significant differences in any of the 5 study outcomes between those reaching seizure freedom at week 16-20 (n 5 177) and those who did not (n 5 101). However, post hoc group comparisons controlling for baseline scores showed the negative effects of valproic acid relative to ethosuximide and lamotrigine treatment, beneficial effects of seizure freedom, and the influence of baseline CBCL score for the week 16-20 visit total problems, internalizing problems, and externalizing problems scores (tables 4, e-2, and e-3).
At week 16-20, all 5 study behavioral outcomes were significantly worse in participants with week 16-20 visit CPT confidence index scores $0.60 (n 5 82) compared to those participants with week 16-20 visit CPT confidence index scores ,0.60 (n 5 149) when the analysis controlled for baseline CBCL scores. When analyzed by both treatment and week 16-20 confidence index, both a treatment effect and CPT confidence index effect were noted. Valproic acid use and CPT confidence index $0.60 were associated with worsening total problems scores.
Month 12 CBCL scores. For the 168 participants who had a CBCL at month 12, there were no differences in total problems, internalizing problems, externalizing problems, or attention-deficit/hyperactivity problems scores between treatment groups. However, patients taking valproic acid had a higher mean attention problems score and a higher percentage of attention problems scores $70 compared to patients taking ethosuximide and patients taking lamotrigine (table 2) .
Pairwise comparison within the ANOVA using a Bonferroni correction but not controlling for baseline revealed the valproic acid group had worse attention problems scores (57.9 [98.3% CI 55.6-60.3]) compared to the ethosuximide group (54.5 [98.3% CI 52.1-56.9]). When controlling for baseline scores, the valproic acid-ethosuximide difference remained significant (table e-1).
Controlling for baseline CBCL scores, there was no difference in month 12 behavioral outcomes between those who remained seizure-free (n 5 123) and those who did not (n 5 15) except for slightly worse attention problems scores in those experiencing treatment failure (58.9 6 10.55 vs 55.6 6 6.51; p 5 0.032). Total, externalizing, and attention problems were worse in participants with month 12 CPT confidence index scores $0.60 (n 5 47) than in those with month 12 confidence index scores ,0.60 (n 5 78) controlling for baseline CBCL scores.
For the 138 participants with a CBCL both at baseline and at month 12, there was a modest but significant improvement between visits in total problems score and all secondary outcomes except attention-deficit/hyperactivity problems (table 3) . There were no significant differences in the 5 study behavioral outcomes by treatment between week 16-20 and month 12.
DISCUSSION This study identified preexisting behavioral problems in children with CAE. The subsequent behavioral assessments identified differential negative effects of valproic acid compared to ethosuximide and lamotrigine as well as negative effects of ongoing seizures and pretreatment behavior problems.
Although this RCT did not include a control group, the percentage of participants with total problems scores $70 (8%; 95% CI 6%-11%) is higher than would be expected of a healthy control group (2.1%) since all scores are normalized to a mean of 50 with a standard deviation of 10. CBCL subscales demonstrated this same elevation relative to an expected healthy control group (table 1) .
Recently, there has been increased recognition of the comorbidities of cognition and behavior in children with epilepsy. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 23 Studies of large cohorts of children with newly diagnosed epilepsy have shown that these comorbidities are often present at baseline and likely predate the onset of clinical seizures. 4, 6, 23 Austin and colleagues 4 examined a cohort of schoolaged children with newly diagnosed epilepsy including both generalized and localization-related syndromes using the CBCL. They found an increased risk of total problems, as well as internalizing problems, attention problems, thought problems, and somatic complaints, in children with new-onset seizures compared to their siblings without seizures. Hermann and colleagues 6 found that the inattentive form of attention-deficit/hyperactivity disorder was significantly more prevalent in their group of children (8-18 years) with newly diagnosed idiopathic epilepsy than in healthy controls and that in the majority it occurred prior to the diagnosis of epilepsy. This is consistent with our findings 15, 16 and may explain why parental report of attention, which is often based on hyperactivity, does not correlate well with formal measurements of attention such as the CPT 15 in this study. However, there is still an increase in other behavior problems as well and this is consistent with other studies. 3, 4, [8] [9] [10] [12] [13] [14] More recent literature suggests that behavior problems as well as issues with cognition are present in even the most benign forms of epilepsy at diagnosis regardless of whether medications are initiated. [24] [25] [26] [27] Psychiatric comorbidities and behavior problems are also increased in children with epilepsy. They occur in children with both localization-related and generalized epilepsy including CAE.
3,4,6-14 Studies focusing on CAE have reported that, compared to normal controls, children with CAE have higher rates of attention-deficit, anxiety, and affective disorders as well as of suicidal ideation. 3, [8] [9] [10] Our study of newly diagnosed CAE demonstrates that these are present at baseline and allows us to examine medication effects.
Some studies suggest that while behavioral problems exist at baseline in children with epilepsy, they improve over time, 4 and we did find modest improvement in the first year in those participants remaining in the study. Not surprisingly, family variables have an important effect on behavioral outcomes. 4 However, long-term outcomes of CAE show a high rate of behavioral issues and poor academic performance. 3 The current CAE study is examining long-term outcomes and will ultimately be able to correlate them with baseline behavior scores.
It is not surprising that increased behavioral problems correlate with poorer performance on measures of cognition including attention, executive function, and intelligence. 4, 23 The worse reported behavioral outcomes in the children $6 years may partly be a caregiver recognition issue. Attention issues and aggressive behavior are more noticeable and less acceptable to parents of older children. The long-term follow-up will determine if there is a difference once the children are older. But while older age at onset has a higher rate of developing generalized tonic-clonic seizures, 28 this report identifies that older age at onset is also associated with more behavioral comorbidities in CAE.
Both treatment assignment and seizure outcomes affected behavioral outcomes. Those assigned to valproic acid did substantially worse than those assigned to ethosuximide or lamotrigine. Behavioral outcomes for lamotrigine are not better than those for ethosuximide. These data reinforce the compelling result that ethosuximide is the preferred first-line treatment for CAE absence [15] [16] [17] 28 as it has superior efficacy to lamotrigine and fewer cognitive and behavioral adverse effects than valproic acid. An analysis of a prospective observational cohort also reported better long-term seizure outcomes in those initially treated with ethosuximide than those treated with valproic acid. 29 This RCT, with longitudinal behavioral assessments, identified an elevated rate of pretreatment behavioral issues in children with CAE, the relationships between negative behaviors and ongoing seizures and attention problems, and that ethosuximide is the preferred initial monotherapy for children with CAE.
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